Summary of Guardant Health Conference Call Company Overview - **Company**: Guardant Health - **Industry**: Life Sciences Tools and Diagnostics Key Points Business Drivers and Growth Opportunities - Guardant Health has three major business drivers: treatment selection, minimal residual disease (MRD), and screening, all contributing to hypergrowth opportunities [4][5][6] - The SERENA-6 trial is a significant growth driver for Guardant360, focusing on liquid biopsy for treatment selection in breast cancer patients [4][9] - The FDA approval for the ESR1 mutation detection is anticipated in the first half of the year, which could double the volume of breast cancer testing [5][9] Clinical Utility and Testing - The ESR1 mutation is a mechanism of resistance in breast cancer, and its detection can influence treatment decisions [5][6] - Guardant360 is set to become the first monitoring companion diagnostic (CDx) for liquid biopsy, expanding its utility beyond single time-point testing [10][12] - The company has seen a significant increase in testing volume post-FDA approvals, which enhances conversations with commercial payers regarding reimbursement [12][14] Product Development and Technology - Guardant Health is leveraging a large database of genomic and epigenomic data to enhance its product offerings, including the development of Smart Apps for clinical information [13][14] - The Reveal product is the fastest-growing test in the portfolio, with expectations for continued growth in both adjuvant and surveillance settings [16][19] - The Reveal Ultra launch is anticipated later this year, with the potential for significant market impact, although it is not included in the 2026 revenue guidance due to uncertainties [35][36] Market Strategy and Adoption - The Shield product targets unscreened patient populations, with 90% of tested patients having not been screened in the last five years, indicating a substantial market opportunity [42][52] - Guardant Health is focusing on increasing productivity among existing sales representatives and expanding its sales force to drive growth [43][46] - The company is not yet competing directly with stool-based tests but is seeing some incidental use cases where patients prefer blood tests over traditional methods [52] Reimbursement and Financial Outlook - Current reimbursement for CRC surveillance is approximately $1,644, with expectations for similar levels for new products [36][37] - The company is optimistic about future reimbursement discussions as it continues to engage with commercial payers [12][37] Future Opportunities - There is potential for future advancements in MRD testing, including the ability to locate and characterize residual disease through the same test [24][32] - Guardant Health is exploring the integration of multi-omics data to enhance its diagnostic capabilities [13][14] Additional Insights - The company is strategically positioning itself to fill care gaps in cancer screening, particularly among populations that have not previously engaged with screening technologies [42][52] - Guardant Health's approach to direct-to-consumer (DTC) marketing is evolving, with a focus on educating consumers about the importance of screening [53][54]

Core Insights - Guardant Health reported a significant year in 2025, with total revenue increasing by 39% year over year to $281.3 million in Q4 and 33% to $982.0 million for the full year [2][4]. - The company achieved an adjusted EBITDA loss of $64.9 million in Q4, an improvement from $78.4 million in the prior-year quarter, and a full-year loss of $220.9 million compared to $257.5 million in 2024 [1][4]. - Management expects revenue for 2026 to be between $1.25 billion and $1.28 billion, indicating a growth rate of 27% to 30% [3][18]. Financial Performance - Adjusted EBITDA loss narrowed to $64.9 million in Q4 from $78.4 million in the prior-year quarter, with a full-year loss of $220.9 million compared to $257.5 million in 2024 [1]. - Non-GAAP gross margin improved to 66% in Q4, up from 63% a year earlier, and remained at 66% for the full year, up from 62% in 2024 [1]. - Free cash flow burn was $233 million in 2025, an improvement of $42 million, with the core business generating positive free cash flow in Q3 and Q4 [8]. Product and Market Growth - Oncology revenue grew by 30% year over year to $189.9 million in Q4, with test volumes rising 38% to approximately 79,000 [9]. - The Shield screening product generated $35.1 million in Q4 from approximately 38,000 tests, with a total of $79.7 million for the full year from around 87,000 tests [5][14]. - The company highlighted the strong adoption of key products such as Guardant360, Reveal, and Shield, with Reveal being the fastest-growing oncology product [3][11]. Strategic Initiatives - Guardant is expanding its partnerships and commercialization efforts, including collaborations with Quest Diagnostics and PathGroup to broaden access to its products [19]. - The company plans to invest incremental screening gross profit into sales and marketing buildout in 2026, aiming to enhance its market presence [16]. - Management emphasized the importance of reimbursement efforts for additional use cases of Reveal, which could drive future growth [12]. Future Outlook - For 2026, Guardant expects oncology revenue growth of 25% to 27%, supported by approximately 30% volume growth [18]. - The company is targeting company-wide free cash flow breakeven by the end of 2027, with the core business expected to be free cash flow positive in 2026 [3][7]. - Guardant plans to launch Reveal Ultra in 2026, which is anticipated to have best-in-class clinical sensitivity in the tumor-informed MRD space [13].

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $281 million, representing a 39% year-over-year growth, while full-year revenue reached $982 million, a 33% increase year-over-year [9][31] - Non-GAAP gross margin improved to 66% in Q4 2025, up from 63% in the prior year, driven by a significant reduction in Reveal cost per test [32][33] - Adjusted EBITDA loss improved to $64.9 million in Q4 compared to $78.4 million in the prior year quarter [34] Business Line Data and Key Metrics Changes - Oncology revenue increased 30% to $190 million in Q4, with volumes growing 38% to approximately 79,000 tests [9][29] - Screening revenue totaled $35 million from approximately 38,000 Shield tests in Q4, reflecting strong sequential growth [19][30] - Biopharma and data revenue grew 18% year-over-year to $210 million in 2025 [16][17] Market Data and Key Metrics Changes - Guardant360 Liquid volumes increased nearly 30%, supported by expanding clinical utility from Smart apps launched over the past year [30] - Reveal continued to be the fastest-growing oncology product, benefiting from CRC surveillance reimbursement and early uptake for late-stage therapy response monitoring [12][30] - Shield's adherence rate reached 93% across the first 100,000 tests ordered, significantly higher than other screening modalities [22] Company Strategy and Development Direction - The company aims to expand Shield to include multi-cancer detection results, enhancing its market position [24] - Strategic collaborations with Quest Diagnostics and PathGroup are expected to broaden national reach and enhance commercial infrastructure [23] - The acquisition of MetaSyte Diagnostics is anticipated to enhance the oncology product portfolio and accelerate multi-disease detection capabilities [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026, expecting revenue growth of 27%-30% and oncology revenue growth of 25%-27% [36][37] - The company is focused on achieving cash flow breakeven by the end of 2027, with expectations of positive free cash flow from the core business in 2026 [35][40] - Management highlighted the importance of reimbursement wins for therapy monitoring as a significant growth driver for the oncology business [46] Other Important Information - The company reported a significant increase in the commercial team, with approximately 300 sales representatives by the end of 2025 [21] - The ADLT reimbursement rate for Shield is set at $1,495, secured through December 2027, supporting healthy ASP and gross profit [25][39] - The company is actively pursuing FDA approvals for new products, including Guardant360 Liquid CDx for lung cancer [40] Q&A Session Summary Question: Can you elaborate on Reveal therapeutic monitoring and its opportunity? - Management expressed excitement about Reveal for therapy monitoring, emphasizing its synergy with Guardant360 for patient treatment decisions [44][46] Question: How should we think about oncology growth throughout the year? - Management is bullish about 2026, expecting at least 20% growth in Guardant360 volumes and strong performance from Reveal [50][51] Question: What is the expected burn for Shield in 2026? - The company anticipates a similar burn for screening as in 2025, around $220 million, while the rest of the business is expected to be cash flow positive [54][55] Question: What is the latest thinking on ADLT pricing for Guardant360? - Management indicated that no ADLT pricing is baked into the 2026 guidance, with expectations for FDA submission in H2 2026 [59][61] Question: Can you discuss the opt-in rate for MCED Shield and its potential for FDA approval? - Management reported good adoption rates for the MCED offering, with enthusiasm from providers and patients, but did not provide specific numbers [76][78]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $281 million, representing a 39% year-over-year growth, while full-year revenue reached $982 million, a 33% increase year-over-year [9][31] - Non-GAAP gross margin improved to 66% in Q4 2025, up from 63% in the prior year, driven by a significant reduction in Reveal cost per test [32] - Adjusted EBITDA loss improved to $64.9 million in Q4 2025, compared to $78.4 million in the prior year quarter [34] Business Line Data and Key Metrics Changes - Oncology revenue increased 30% to $190 million in Q4 2025, with oncology volumes growing 38% to approximately 79,000 tests [9][29] - Screening revenue totaled $35 million from approximately 38,000 Shield tests in Q4 2025, reflecting strong sequential growth [19][30] - Biopharma and data revenue grew 18% year-over-year to $210 million in 2025 [16][17] Market Data and Key Metrics Changes - Guardant360 Liquid volumes increased nearly 30%, supported by expanding clinical utility from SMART apps launched over the past year [30] - Reveal continued to be the fastest-growing oncology product, benefiting from CRC surveillance reimbursement and early uptake for late-stage therapy response monitoring [12][30] - Shield's adherence rate reached 93% across the first 100,000 tests ordered, significantly higher than other screening modalities [22] Company Strategy and Development Direction - The company aims to expand its multi-cancer detection capabilities with Shield, which now includes a multi-cancer detection result report [24] - Strategic collaborations with Quest Diagnostics and PathGroup are expected to broaden national reach and enhance commercial infrastructure [23] - The acquisition of MetaCyte Diagnostics is anticipated to enhance the oncology product portfolio and accelerate the multi-disease detection pipeline [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued strong growth in oncology, expecting 25%-27% revenue growth in 2026, supported by volume growth of approximately 30% [37] - The company anticipates free cash flow positive status for the core business in 2026, with a commitment to achieving company-wide cash flow breakeven by the end of 2027 [35][36] - Management highlighted the importance of reimbursement wins for therapy monitoring as a significant growth driver for the oncology business [46] Other Important Information - The company has established a robust pipeline of ongoing companion diagnostics programs, with 25 approvals to date across the U.S., Japan, and Europe [17] - The company expects to launch several new products in oncology, including Guardant360 Liquid CDx for lung FDA approval and Reveal Ultra [40] Q&A Session Summary Question: Can you elaborate on Reveal therapeutic monitoring and its opportunity? - Management expressed excitement about Reveal for therapy monitoring, emphasizing its synergy with Guardant360 for monitoring patient responses to therapies [44][46] Question: How should we think about the growth of oncology products throughout the year? - Management is bullish about 2026, expecting at least 20% growth in Guardant360 volumes and strong performance from Reveal [50][51] Question: What is the expected burn for Shield and the pacing of rep hiring in 2026? - The company anticipates a similar burn for screening as in 2025, around $220 million, while continuing to build out the commercial organization [54][56] Question: What is the latest thinking on ADLT pricing for Guardant360? - Management indicated that no ADLT pricing is baked into the 2026 guidance, with expectations for FDA submission in the second half of the year [60][61] Question: Can you discuss the opt-in rate for MCED Shield and potential FDA submission? - Management reported good adoption rates for the MCED offering, with enthusiasm from providers and patients, but did not disclose specific numbers [78]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $281.3 million, representing a 39% year-over-year growth, while full-year revenue reached $982.0 million, a 33% increase year-over-year [7][28]. - Non-GAAP gross margin improved to 66% in Q4 2025, up from 63% in the prior year, and for the full year, it increased from 62% in 2024 to 66% [29][30]. - Adjusted EBITDA loss improved to $64.9 million in Q4 compared to $78.4 million in the prior year, and for the full year, the loss was $220.9 million versus $257.5 million in 2024 [31]. Business Line Data and Key Metrics Changes - Oncology revenue increased by 30% to $189.9 million in Q4, with approximately 79,000 tests conducted, reflecting a 38% volume growth [25][28]. - Screening revenue totaled $35.1 million from approximately 38,000 Shield tests in Q4, with an average selling price (ASP) of approximately $850 [27][30]. - Biopharma and data revenue grew 9% to $54.0 million, aligning with expectations [27]. Market Data and Key Metrics Changes - The company received Medicare coverage for colorectal cancer (CRC) surveillance in early 2025, which has positively impacted the adoption of Reveal [5]. - The Shield test has shown strong adherence rates of 93% among patients, significantly higher than traditional screening methods [18]. Company Strategy and Development Direction - The company aims to expand its multi-cancer detection capabilities through the Shield platform, which includes a new multi-cancer detection results report [21]. - Strategic partnerships with Quest Diagnostics and PathGroup are expected to enhance national reach and operational capabilities in 2026 [19][20]. - The acquisition of MetaCyte Diagnostics is anticipated to enhance the company's R&D capabilities and accelerate its multi-disease detection pipeline [32]. Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued strong growth in oncology, projecting a 25%-27% growth rate for oncology revenue in 2026, supported by volume growth of approximately 30% [33]. - The company expects to achieve free cash flow positivity for the core business in 2026, excluding screening, and aims for company-wide cash flow breakeven by the end of 2027 [32][36]. - Management highlighted the importance of reimbursement wins for therapy monitoring as a significant growth driver for the oncology business [42]. Other Important Information - The company has established a robust pipeline of ongoing companion diagnostics (CDx) programs, with 25 approvals to date across various regions [14]. - The company is focused on improving gross margins through ASP optimization and operational efficiencies, with expectations of non-GAAP gross margins in the range of 64%-65% for 2026 [36]. Q&A Session Summary Question: Can you elaborate on Reveal therapeutic monitoring and its opportunity? - Management expressed excitement about Reveal for therapy monitoring, emphasizing its synergy with Guardant360 for patient monitoring and therapeutic decisions [40][42]. Question: How should we think about oncology growth throughout the year? - Management is bullish about 2026, expecting at least 20% growth in Guardant360 volumes and strong performance from Reveal, which is anticipated to remain the fastest-growing product [46][48]. Question: What is the expected burn for Shield in 2026? - The company anticipates a similar burn level for screening as in 2025, around $220 million, while the rest of the business is expected to be free cash flow positive [50][52]. Question: What is the latest on ADLT pricing for Guardant360? - Management indicated that no ADLT pricing is baked into the 2026 guidance, with expectations for FDA submission progress in the second half of the year [58][59]. Question: Can you discuss the opt-in rate for MCED Shield and potential FDA submissions? - Management noted good adoption rates for the MCED offering, with enthusiasm from providers and patients, but did not provide specific numbers [76][78].

Conquering Cancer with Data Q4 2025 & Full Year 2025 Earnings Call February 19, 2026 Safe harbor and non-GAAP disclosures Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws. These statements relate to future events or Guardant Health, Inc. (the "Company")'s future results and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance ...

JP Morgan Healthcare Conference J anuary 12, 2026 Safe harbor and non-GAAP disclosures Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of federal securities laws. These statements relate to future events or Guardant Health, Inc. (the "Company")'s future results and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or i ...

Summary of Guardant Health FY Conference Call Company Overview - **Company**: Guardant Health (NasdaqGS:GH) - **Industry**: Life Sciences, Tools, and Diagnostics Key Financial Targets - **Revenue Target**: $2.2 billion by 2028, with a potential aspiration of $5 billion [2][4] - **Oncology Revenue**: Expected to be $1.4 billion by 2028, accounting for over 60% of total revenue [4][6] - **Biopharma Revenue**: Forecasted to grow from $200 million to $300 million by 2028 [5] - **Screening Revenue**: Projected to reach $500 million by 2028, representing approximately 25% of total revenue [6] Product Performance and Growth - **Guardant360**: Continues to grow at approximately 30% year-over-year, driven by increased orders per oncologist and new SMART apps [7][10] - **Reveal**: Fastest-growing oncology product, with potential for new indications and therapy monitoring applications [5][12] - **Shield**: Expected to contribute significantly to revenue, with a target of $500 million by 2028 [6] Market Dynamics - **Oncology Market**: Guardant360 has penetrated the oncology market well, with over 10,000 oncologists ordering the test annually [7] - **Liquid Biopsy**: The company believes that centralized lab business will remain dominant due to the complexity of services offered compared to hospital labs [24] Regulatory and Reimbursement Strategies - **ADLT Submission for Reveal**: Ongoing process with potential upside if approved, targeting an ASP of $1,000 by 2028 [14][16] - **Medicare Reimbursement**: Critical for achieving ASP targets and driving revenue growth [16] Operational Efficiency and Cost Management - **Cost of Goods Sold (COGS)**: Targeting $200 per test for Shield, with current costs below $500 [17][29] - **Gross Margin Targets**: Expecting gross margins of 65-70% across the product portfolio by 2028 [29][30] Sales and Marketing Strategy - **Sales Force Expansion**: Currently over 250 sales representatives, with plans for continued ramp-up [35] - **Partnership with Quest**: Aims to leverage Quest's extensive network to enhance market penetration [35] Future Outlook and Strategic Initiatives - **Breakeven Target**: Committed to achieving breakeven by the end of 2027, with no changes to the plan despite recent funding [26][27] - **M&A Opportunities**: Focused on acquiring technologies that enhance product offerings, with a preference for smaller deals [39][40] Clinical Trials and Product Development - **SERENA-6 Protocol**: Anticipated to be a significant catalyst for product adoption and market expansion [37][38] Conclusion - Guardant Health is positioned for strong growth in the oncology diagnostics market, with a clear strategy for revenue generation, operational efficiency, and market expansion through innovative products and strategic partnerships. The company remains focused on achieving its financial targets while navigating regulatory landscapes and enhancing its product offerings.

Summary of Guardant Health Q3 2025 Conference Call Company Overview - **Company**: Guardant Health (NasdaqGS:GH) - **Industry**: Life Sciences, specifically focused on liquid biopsy and cancer diagnostics Key Highlights from Q3 2025 - **Strong Performance**: Q3 was characterized by strong volumes and positive developments across all product lines, including Guardant 360 Liquid and Guardant 360 Tissue launches [2][3] - **Product Launches**: The quarter marked the first full launch of 11 new smart applications on the Guardant 360 Liquid platform, contributing to significant quarter-over-quarter and year-over-year growth [2] - **Market Reception**: There was notable excitement in the field for the Guardant 360 Tissue test, which includes full DNA, RNA, and methylation analysis [2] Future Growth Drivers - **2026 Outlook**: Anticipated continued momentum in 2026 with new product launches and therapy monitoring capabilities [5] - **Key Catalysts**: Potential approval of chemosestrant from the Serena 6 trial and PMA submission for Guardant 360 Liquid expected to drive growth [5][6] - **Shield Product**: Shield is projected to have a strong year in 2026, with revenues expected to exceed $100 million [7] Market Expansion and Partnerships - **Patient Population**: The company is targeting a $50 million on-screen patient population, indicating significant room for growth [8] - **Partnerships**: Collaborations with Quest Diagnostics and PathGroup are expected to enhance market access and EMR integration, facilitating broader adoption of Shield [9] Adherence and Screening Trends - **Adherence Rates**: Shield-based screening has shown a 95% adherence rate, which is expected to support sustained growth in colorectal cancer (CRC) screening [10] - **Market Potential**: It is estimated that at least 20% of patients will opt for blood-based modalities for CRC screening, indicating a shift in patient preferences [11] Sales Force and Productivity - **Sales Force Expansion**: The sales team has grown from 100 to over 250 representatives, with plans to reach 600-700 by the end of 2026 [13] - **Rep Productivity**: New representatives are becoming productive faster than expected, contributing significantly to growth [15] Regulatory and Guideline Developments - **NCCN Inclusion**: Shield has been included in NCCN guidelines, which is a significant endorsement from oncology experts [17] - **Future Guidelines**: Anticipation of inclusion in American Cancer Society guidelines and monitoring of USPSTF developments [18] Multi-Cancer Detection Initiatives - **Data Collection**: The launch of multi-cancer detection testing is expected to provide valuable data for future research and development [19][20] - **Screening Age Trends**: There is a growing concern about the rising incidence of CRC in younger populations, which may lead to a future reduction in screening age [21] Financial Performance and Cost Management - **Revenue Growth**: Guardant 360 reported over 30% growth with volumes up 40% in Q3 [33] - **Cost of Goods Sold (COGS)**: COGS for Reveal has decreased significantly, with expectations to further reduce costs through increased volume and automation [26][27] ASP and Market Positioning - **Average Selling Price (ASP)**: Current ASP for Guardant 360 is in the $3,000-$3,100 range, with potential for improvement through expanded commercial coverage and new indications [38] - **Medicare Advantage Payments**: Strong Medicare Advantage payments are driving ASP growth for Shield, currently around $900 [40] Conclusion - Guardant Health is positioned for significant growth in the coming years, driven by innovative product launches, strategic partnerships, and a strong sales force. The company is actively addressing market needs and regulatory changes to enhance its competitive position in the cancer diagnostics industry.

Financial Data and Key Metrics Changes - Total revenue for Q3 2025 grew 39% year-over-year to $265.2 million, marking the first time annualized revenue surpassed $1 billion [6][25] - Non-GAAP gross margin improved to 66% in Q3 2025, up from 63% in the prior year, driven by reduced costs [29] - Adjusted EBITDA loss was $45.5 million, an improvement from a loss of $56.2 million in Q3 2024 [30] Business Line Data and Key Metrics Changes - Oncology revenue increased 31% to $184.4 million, with approximately 74,000 tests performed, reflecting a 40% growth in volume [8][25] - Screening revenue from Shield totaled $24.1 million, generated from 24,000 tests, with an average selling price (ASP) of approximately $880 [28] - Biopharma and data revenue grew 18% year-over-year to $54.7 million, supported by two companion diagnostic approvals [27] Market Data and Key Metrics Changes - The screening business is tracking at an annual run rate of approximately $100 million, one year into the commercial launch of the FDA-approved product [6] - Shield tests have shown high adherence rates, with over 90% of ordered cases resulting in completed blood samples [18] Company Strategy and Development Direction - The company aims to expand its commercial infrastructure for Shield, leveraging partnerships with Quest Diagnostics and Path Group to enhance access [19][20] - Continued investment in commercial initiatives and the introduction of new smart applications are expected to drive future growth [14][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential inclusion of Shield in American Cancer Society guidelines, which could enhance commercial coverage [40][41] - The company raised its full-year 2025 revenue guidance to $965-$970 million, reflecting stronger-than-expected performance [31][32] Other Important Information - The company surpassed 1 million cumulative clinical patients tested, highlighting the impact of its tests in clinical practice [7] - The submission of the PMA application to the FDA for Guardant360 Liquid is expected to streamline the product offering and enhance market adoption [11] Q&A Session Summary Question: Can you walk us through the Shield ASP dynamics exiting the year? - Management indicated that the ASP for Shield is currently around $1,495, with expectations for continued strong payment from Medicare Advantage [36][37] Question: Is guideline inclusion by the American Cancer Society a real possibility by year-end? - Management remains optimistic about the potential inclusion and its positive impact on reimbursement rates, although it will take time to translate into payments [40][41] Question: How should we think about 2026 growth for Shield? - Management is confident about long-term growth but refrained from providing specific guidance for 2026 at this time [45][46] Question: Can you provide any KPIs around average testing frequency per physician? - Management reported high adherence rates, with over 90% of ordered Shield tests being completed [80]